.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,344,478

« Back to Dashboard

Details for Patent: 6,344,478

Title: Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
Abstract:Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor.
Inventor(s): Dean; Thomas R. (Weatherford, TX), May; Jesse A. (Fort Worth, TX), Sallee; Verney L. (Burleson, TX), Desantis, Jr.; Louis (Fort Worth, TX)
Assignee: Alcon Manufacturing, Ltd. (Fort Worth, TX)
Filing Date:Feb 06, 2001
Application Number:09/777,409
Claims:1. A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a composition comprising a therapeutically effective amount of a combination of a carbonic anhydrase inhibitor together with a compound having the absolute stereochemical structure of the following formula (IV): ##STR18##

wherein:

R.sub.1 =H; C.sub.1 -C.sub.12 straight-chain or branched alkyl; C.sub.1 -C.sub.12 straight-chain or branched acyl; C.sub.3 -C.sub.8 cycloalkyl; or a cationic salt moiety;

R.sub.2, R.sub.3.dbd.H, or C.sub.1 -C.sub.5 straight-chain or branched alkyl; or R.sub.2 and R.sub.3 taken together may represent O;

X.dbd.O, S, or CH.sub.2 ;

---- represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;

R.sub.9 =H, C.sub.1 -C.sub.10 straight-chain or branched alkyl, or C.sub.1 -C.sub.10 straight-chain or branched acyl;

R.sub.11 =H, C.sub.1 -C.sub.10 straight-chain or branched alkyl, or C.sub.1 -C.sub.10 straight-chain or branched acyl;

Y=O; or H and OR.sub.15 in either configuration wherein R.sub.15 =H, C.sub.1 -C.sub.10 straight-chain or branched alkyl, or C.sub.1 -C.sub.10 straight-chain or branched acyl; and

Z=Cl or CF.sub.3 ;

with the proviso that when R.sub.2 and R.sub.3 taken together represent O, then R.sub.1.noteq.C.sub.1 -C.sub.12 straight-chain or branched acyl; and when R.sub.2 =R.sub.3 =H, then R.sub.1.noteq.a cationic salt moiety.

2. The method of claim 1, wherein for the compound (IV):

R.sub.2, R.sub.3 taken together represent O;

X=CH.sub.2 ;

---- represents a cis double bond for the alpha (upper) chain and a trans double bond for the omega (lower) chain;

R.sub.9 and R.sub.11 =H; and

Y =OH in the alpha configuration and H in the beta configuration.

3. The method of claim 2, wherein for the compound (IV): Z=CF.sub.3.

4. The method of claim 1, wherein: R.sub.2 =R.sub.3 =H, or R.sub.2 and R.sub.3 taken together represent O; X=O or CH.sub.2 ; R.sub.9 =R.sub.11 =H; Y=H and OR.sub.15 ; and R.sub.15 =H.

5. The method of claim 4, wherein: R.sub.1 =H, C.sub.1 -C.sub.12 straight chain or branched alkyl or cationic salt moiety; and R.sub.2 and R.sub.3 taken together represent O.

6. The method of claim 5, wherein the compound of formula (IV) is selected from the group consisting of cloprostenol, fluprostenol, 3-oxacloprostenol, 13,14-dihydrofluprostenol, and their pharmaceutically acceptable esters and salts.

7. The method of claim 4, wherein the carbonic anhydrase inhibitor is brinzolamide.

8. The method of claim 7, wherein the compound of formula (IV) is fluprostenol isopropyl ester.

9. The method of claim 1, wherein between about 0.01 and about 1000 .mu.g/eye of the compounds of formula (IV) is administered.

10. The method of claim 9, wherein between about 0.1 and about 100 .mu.g/eye of the compound of formula (IV) is administered.

11. The method of claim 10, wherein between about 0.1 and about 10 .mu.g/eye of the compound of formula (IV) is administered.

12. A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension comprising an ophthalmically acceptable carrier and a therapeutically effective amount of a combination of a carbonic anhydrase inhibitor together with a compound having the absolute stereochemical structure of the following formula (IV) and being substantially free of the enantiomer of said compound: ##STR19##

wherein:

R.sub.1 =H; C.sub.1 -C.sub.12 straight-chain or branched alkyl; C.sub.1 -C.sub.12 straight-chain or branched acyl; C.sub.3 -C.sub.8 cycloalkyl; or a cationic salt moiety;

R.sub.2, R.sub.3 =H, or C.sub.1 -C.sub.5 straight-chain or branched alkyl; or R.sub.2 and R.sub.3 taken together may represent O;

X=O, S, or CH.sub.2 ;

---- represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;

R.sub.9 =H, C.sub.1 -C.sub.10 straight-chain or branched alkyl, or C.sub.1 -C.sub.10 straight-chain or branched acyl;

R.sub.11 =H, C.sub.1 -C.sub.10 straight-chain or branched alkyl, or C.sub.1 -C.sub.10 straight-chain or branched acyl;

Y=O; or H and OR.sub.15 in either configuration wherein R.sub.15 =H, C.sub.1 -C.sub.10 straight-chain or branched alkyl, or C.sub.1 -C.sub.10 straight-chain or branched acyl; and

Z=Cl or CF.sub.3 ;

with the proviso that when R.sub.2 and R.sub.3 taken together represent O, then R.sub.1.noteq.C.sub.1 -C.sub.12 straight-chain or branched acyl; and when R.sub.2 =R.sub.3 =H, then R.sub.1.noteq.a cationic salt moiety; and

with the further proviso that the following compound be excluded:

cyclopentane heptenol-5-cis-2-(3-.sub..alpha. hydroxy4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.sub..alpha., 2.sub..beta., 3.sub..alpha., 5.sub..alpha. ].

13. The composition of claim 12, wherein for the compound (IV):

R.sub.2, R.sub.3 taken together represent O;

X=CH.sub.2 ;

---- represents a cis double bond for the alpha (upper) chain and a trans double bond for the omega (lower) chain;

R.sub.9 and R.sub.11 =H; and

Y=OH in the alpha configuration and H in the beta configuration.

14. The composition of claim 13, wherein for the compound (IV): Z=CF.sub.3.

15. The composition of claim 14, wherein the carbonic anhydrase inhibitor is brinzolamide and the compound of formula (IV) is travoprost.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc